Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash from Investing Activities data on file, last reported at $11.9 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 373.33% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.5 million (down 177.07% YoY) and the FY2025 annual result came in at $40.3 million, down 30.72% from the prior year.
• Cash from Investing Activities advanced to $11.9 million in Q1 2026, from -$47.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $68.9 million in Q4 2024 to a low of -$145.7 million in Q2 2023.
• A 5-year average of $1.1 million and a median of $11.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 998.57% — and 2024, when it soared 625.3%.
• Tracing ENTA's Cash from Investing Activities over 5 years: stood at $33.6 million in 2022, then plunged by 139.07% to -$13.1 million in 2023, then soared by 625.3% to $68.9 million in 2024, then tumbled by 168.64% to -$47.3 million in 2025, then surged by 125.25% to $11.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $11.9 million (Q1 2026), -$47.3 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.